Skip to main content
SpringerLink
Log in

Who are candidates for prevention and treatment for osteoporosis?

  • Consensus Development Statement
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. Geneva: WHO, 1994.

    Google Scholar 

  2. Cooper C. Campion G, Melton LJ III. Hip fractures in the elderly: a worldwide projection. Osteoporosis Int 1992;2:285–9.

    Google Scholar 

  3. Melton LJ III, Ilstrup DM, Riggs BL, Beckenbaurg RD. Fifty-year trend in hip fracture incidence. Clin Orthop 1982;162;144–9.

    Google Scholar 

  4. Cummings SR, Black DM, Rubin SM. Lifetime risk of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445–8.

    Google Scholar 

  5. Boyce WJ, Vessey MP. Rising incidence of fracture of the proximal femur. Lancet 1985;1:150–1.

    Google Scholar 

  6. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr. Genetic determinants of bone mass in adult women; a reevaluation of the model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res 1991;6:561–7.

    Google Scholar 

  7. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crost L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284–7.

    Google Scholar 

  8. Morrison NA, Yeoman R, Kelly PJ, Eisman JA. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 1992;89:6665–9.

    Google Scholar 

  9. Kobayashi S, Inoue S, Hoso T, Ouchi Y, Shiraki M, Orimo H. Association of bone minoral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 1996;11:306–11.

    Google Scholar 

  10. Heaney RP, Recker RR. Effects of nitrogen, phosphorus and caffeine on calcium balance in women. J Lab Clin Med 1982;99:46–55.

    Google Scholar 

  11. Nordin BEC, Morris HA. The calcium deficency model for osteoporosis. Nutr Rev 1989;47:65–72.

    Google Scholar 

  12. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961–4.

    Google Scholar 

  13. Ensrud KE, Palermo L, Black DM, Cauley JA, Jergas M, Orwoll ES, et al. for the Study of Osteoporotic Fractures Research Group. Hip bone loss increases with advancing age: longitudinal results from the study of osteoporotic fractures [Abstract]. J Bone Miner Res 1944;9(Suppl 1):S153.

    Google Scholar 

  14. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss. J Clin Invest 1996;97:14–21.

    Google Scholar 

  15. Kanis JA. Cuases of osteoporosis, In: Osteoporosis. Oxford: Blackwell Scientific, 1994:81–113.

    Google Scholar 

  16. Clinical indications for bone mass measurements. A report from the Scientific Advisory Board of the National Osteoporosis Foundation.1989;4:1–28.

  17. Melton LJ III, Atkinson EJ, O'Fallon WM, Whaner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33.

    Google Scholar 

  18. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72–5.

    Google Scholar 

  19. Hans D, Dargent P, Schott AM, Sebert JL, Cormier C, Kotski PO, et al. Ultrasound parameters predict hip fracture independently of hip bone density: the EDIPOS prospective study. Seventeenth Annual Meeting of the American Society for Bone and Mineral Research, September, 1995, abstract 123.

  20. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture. A 15-year follow-up study. Bone 1996;19:9–12.

    Google Scholar 

  21. Riis BJ, Overgaard K, Christiansen C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos Int 1995;5:276–80.

    Google Scholar 

  22. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993;341:11–3.

    Google Scholar 

  23. Bush TL, Barret-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation 1987;75:1102–9.

    Google Scholar 

  24. Christiansen C, Christiensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459–61.

    Google Scholar 

  25. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (I.Y139481) HC: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835–42.

    Google Scholar 

  26. Riis BJ, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind controlled study. N Engl J Med 1987;316:173–7.

    Google Scholar 

  27. Chapuy MC, Arlot ML, DuBoef F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.

    Google Scholar 

  28. Iverson E, Hassager C, Christiansen C. The effect of hemiplegia on bone mass and soft tissue body composition. Acta Neurol Scand 1989;79:155–9.

    Google Scholar 

  29. Kanis JA. Prevention of osteoporosis from menarche to menopause, In: Osteoporosis. Oxford:Blackwell Scientific, 1994:148–67.

    Google Scholar 

  30. Grady D, Rubin SM, Petitti, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37.

    Google Scholar 

  31. Liberman UA, Weiss SR, Broil J, Minne HW, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–43.

    Google Scholar 

  32. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61.

    Google Scholar 

  33. Riggs BL, O'Fallon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994;9:265–75.

    Google Scholar 

  34. Geusens P, Dequeker J, Verstraeten A, et al. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3 or intermittent calcium infusions. Maturitas 1986–8:281–9.

    Google Scholar 

  35. Tilyard M, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.

    Google Scholar 

  36. Lindsay R, Cosman F, Nieves J, et al. A controlled clinical trial of the effects of 1–34 hPTH in estrogen treated osteoporotic women. J Bone Miner Res 1993;(Suppl 1):S130.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Who are candidates for prevention and treatment for osteoporosis?. Osteoporosis Int 7, 1–6 (1997). https://doi.org/10.1007/BF01623453

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01623453

Keywords

Search

Navigation